Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
NASDAQ:RVNC
Revance Therapeutics (RVNC) Stock Price & Analysis
558 Followers
RVNC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.59 - $32.45
Previous Close$2.84
Volume2.63M
Average Volume (3M)2.03M
Market Cap
$296.63M
Enterprise Value$521.15M
Total Cash (Recent Filing)$253.91M
Total Debt (Recent Filing)$478.43M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 06, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.63
Shares Outstanding104,448,502
10 Day Avg. Volume2,097,478
30 Day Avg. Volume2,031,252
Standard Deviation0.24
R-Squared0.07
Alpha-0.00642
Financial Highlights & Ratios
Price to Book (P/B)-1.84
Price to Sales (P/S)1.27
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.23
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$12.00Price Target Upside298.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Revance Therapeutics News
PremiumCompany Announcements
Revance Therapeutics Launches DAXXIFY® for Cervical Dystonia
Bulls Say, Bears Say
Bulls Say
Financial GuidanceThe company reiterated its 2024 top-line guidance of ≥$280MM, indicating confidence in its revenue growth.
Market Share GrowthRHA filler continues to gain market share and the launch of RHA3 for lip augmentation could stimulate further growth.
Product StrategyThe company's new pricing strategy and improved product quality are likely to contribute to customer loyalty and deeper market penetration.
Bears Say
Earnings DisappointmentEPS loss was wider than consensus, and the top line missed our below-consensus forecast.
Market PerceptionThe mixed reception of Daxxify within the aesthetics community may lead to new accounts approaching with caution.
Product PerformanceDaxxify's revenue fell short of expectations with a quarter-over-quarter decrease, raising concerns about meeting the annual guidance.
---
Ownership Overview
12.84% Insiders
34.89% Mutual Funds
48.99% Other Institutional Investors
3.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $2.59 and its highest was $32.45 in the past 12 months.
What is Revance Therapeutics’s market cap?
Currently, no data Available
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 63 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on May 09, 2024. The company reported -$0.443 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.019.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,448,500 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.443 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -22.611%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Perceptive Advisors LLC. It holds Revance Therapeutics’s shares valued at 3M.
---
Revance Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (298.67% Upside)
$12.00 (298.67% Upside)
Blogger Sentiment
Neutral
RVNC Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 710.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.24%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
RVNC Earnings Call
Q1 2024
0:00 / 0:00
---
RVNC Stock 12 Month Forecast
Average Price Target
$12.00
▲(298.67% Upside)
Technical Analysis
SAGE Therapeutics
―
BioMarin Pharmaceutical
―
ACADIA Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering RVNC
1 Year
1 Year Success Rate
15/36 ratings generated profit
1 Year Average Return
-8.61%
reiterated a buy rating 25 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -8.61% per trade.
---